New glaucoma testing device praised

Article

The TrueField Analyser, a glaucoma testing device, has been hailed by reseachers at the Australian National University as offering faster, more comprehensive and more accurate diagnoses than current methods.

The TrueField Analyser, a glaucoma testing device, has been hailed by researchers at the Australian National University as offering faster, more comprehensive and more accurate diagnoses than current methods.

The heads of research, Dr Andrew James and Ted Maddess, who developed the device in collaboration with Seeing Machines Ltd, explained how the multifocal pupillographic perimetry produces a more consistent result by measuring pupil responses to just 88 visual stimuli; the device also makes measurements for both eyes simultaneously, and monitors these on a video camera system. These modifications to the traditional testing method produce a faster, objective and reproducible image, and also produce information on the brain and retinal function.

The researchers presented the results of a study demonstrating the commercial viability of the TrueField Analyser at the 29th annual Australian Neuroscience Society held in Canberra in January. Seeing Machines Ltd anticipates the device will be available by the middle of the year.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
© 2025 MJH Life Sciences

All rights reserved.